<DOC>
	<DOCNO>NCT03062956</DOCNO>
	<brief_summary>Up 56 healthy volunteer give single dose MYK-491 placebo monitor safety tolerability 7 day period .</brief_summary>
	<brief_title>A Single Ascending Dose Study Assessing Safety , Tolerability , PK PD MYK-491</brief_title>
	<detailed_description>Up 56 healthy volunteer give single dose MYK-491 placebo monitor safety tolerability 7 day period . After 28 day screen period , eligible subject admit clinical site receive single dose study drug placebo . Subjects confine clinical site five day ( Day -1 Day 4 ) return clinic Day 7 safety follow-up .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Weight 60 90 kg inclusive Resting heart rate &lt; 80 beat per minute Documented LVEF great equal 55 % Screening Normal electrocardiogram ( ECG ) Screening Normal acoustic window transthoracic echocardiogram Screening All safety laboratory parameter within normal limit Screening History evidence another clinically significant disorder , opinion investigator . Active infection History coronary artery disease History malignancy exception situ cervical cancer 5 year prior Screening surgicallyexcised nonmelanomatous skin cancer 2 year prior Screening Positive serology test screen Current use tobacco nicotinecontaining product exceed 10 per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>